Associations between Brain-derived Neurotrophic Factor Val66Met Polymorphism, Melancholic Feature, and Treatment Refractoriness in Patients with Treatment-Resistant Depression

10.4103/TPSY.TPSY_15_22

Yu-Shiou Lin；Shih-Jen Tsai；Mu-Hong Chen

genetics ； heterogenesity effect ； major depressive disorder ； the brain-derived neurotrophic factor homozygous Met/Met polymorphism

台灣精神醫學

36卷2期（2022 / 06 / 01）

68 - 73

英文

Background: Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is related to the pathophysiology of treatment-resistant depression (TRD). But whether the Val66Met polymorphism is associated with the clinical manifestations of TRD (such as treatment refractoriness and melancholic and anxious distress features) remains unclear. Methods: Totally, 106 patients with TRD were genotyped for the BDNF Val66Met polymorphism. We used the 17-item Hamilton Depression Rating Scale evaluate depressive symptoms (melancholic and anxious distress features) and Maudsley Staging Method to measure treatment refractoriness. Logistic regression models were constructed to study the relationships among the Val66Met polymorphism, melancholic or anxious distress features, and treatment refractoriness. Results: The risk of Val/Met heterozygosity was associated with significantly greater melancholic features than that of Val/Val homozygosity (odds ratio [95% confidence interval (CI)] = (4.67 [1.16-14.24], p ＜ 0.05). The melancholic feature in Val/Met heterozygosity was significantly higher to have the risk in treatment refractoriness than that of Val/Val homozygosity odd ratio (95% CI) = (6.42 [1.70-24.25], p ＜ 0.05). Conclusion: Patients with TRD carrying the BDNF Val/Met genotype are more likely to present with melancholic feature, which is in turn related to high treatment refractoriness.

1. Bech, P,Gram, LF,Dein, E(1975).Quantitative rating of depressive states.Acta Psychiatr Scand,51,161-170.
2. Cardoner, N,Soria, V,Gratacòs, M(2013).Val66Met BDNF genotypes in melancholic depression: Effects on brain structure and treatment outcome.Depress Anxiety,30,225-233.
3. Chen, ZY,Patel, PD,Sant, G(2004).Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons.J Neurosci,24,4401-4411.
4. Cleary, P,Guy, W(1977).Factor analysis of the Hamilton depression scale.Drugs Exp Clin Res,1,115-120.
5. Colle, R,Trabado, S,David, DJ(2017).Plasma BDNF level in major depression: biomaker of the Val66Met BDNF polymorphism and of the clinical course in met carrier patients.Neuropsychobiology,75,39-45.
6. Egan, MF,Kojima, M,Callicott, JH(2003).The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.Cell,112,257-269.
7. El-Hage, W,Vourc’h, P,Gaillard, P(2015).The BDNF Val(66)Met polymorphism is associated with escitalopram response in depressed patients.Psychopharmacology,232,575-581.
8. Elzinga, BM,Molendijk, ML,Oude Voshaar, RC(2011).The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met.Psychopharmacology,214,319-328.
9. Fava, M,Rush, AJ,Alpert, JE(2008).Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.Am J Psychiatry,165,342-351.
10. Fekadu, A,Wooderson, SC,Markopoulou, K(2009).The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms.J Clin Psychiatry,70,952-957.
11. Gatt, JM,Nemeroff, CB,Dobson-Stone, C(2009).Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety.Mol Psychiatry,14,681-695.
12. Gili, M,Roca, M,Armengol, S(2012).Clinical patterns and treatment outcome in patients with melancholic, atypical and non-melancholic depressions.PLoS One,7,e48200.
13. Hofer, M,Pagliusi, SR,Hohn, A(1990).Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain.EMBO J,9,2459-2464.
14. Kato, M,Serretti, A(2010).Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.Mol Psychiatry,15,473-500.
15. Kishi, T,Yoshimura, R,Ikuta, T(2017).Brain-derived neurotrophic factor and major depressive disorder: evidence from meta-analyses.Front Psychiatry,8,308.
16. Kotan, Z,Sarandöl, E,Kırhan, E(2012).Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features.Ther Adv Psychopharmacol,2,65-74.
17. Kumar, PK,Mitra, P,Ghosh, R(2020).Association of circulating BDNF levels with BDNF rs6265 polymorphism in schizophrenia.Behav Brain Res,394,112832.
18. Laje, G,Lally, N,Mathews, D(2012).Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.Biol Psychiatry,72,e27-e28.
19. Li, M,Chang, H,Xiao, X(2016).BDNF Val66Met polymorphism and bipolar disorder in European populations: a risk association in case-control, family-based and GWAS studies.Neurosci Biobehav Rev,68,218-233.
20. Ostergaard, SD,Bech, P,Trivedi, MH(2014).Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the research domain criteria (RDoC).J Affect Disord,163,18-24.
21. Pivac, N,Kim, B,Nedić, G(2009).Ethnic differences in brainderived neurotrophic factor Val66Met polymorphism in Croatian and Korean healthy participants.Croat Med J,50,49-54.
22. Primo de Carvalho Alves, L,Pio de Almeida Fleck, M,Boni, A(2017).The major depressive disorder hierarchy: Rasch analysis of 6 items of the Hamilton depression scale covering the continuum of depressive syndrome.PLoS One,12,e0170000.
23. Primo de Carvalho Alves, L,Sica da Rocha, N.(2018).Lower levels of brain-derived neurotrophic factor are associated with melancholic psychomotor retardation among depressed inpatients.Bipolar Disord,20,746-752.
24. Quinn, CR,Dobson-Stone, C,Outhred, T(2012).The contribution of BDNF and 5-HTT polymorphisms and early life stress to the heterogeneity of major depressive disorder: a preliminary study.Aust N Z J Psychiatry,46,55-63.
25. Rimay, T,Benak, I,Kiss, E(2015).BDNF Val66Met polymorphism and stressful life events in melancholic childhood-onset depression.Psychiatr Genet,25,249-255.
26. Rush, AJ,Trivedi, MH,Wisniewski, SR(2006).Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.Am J Psychiatry,163,1905-1917.
27. Rush, AJ,Warden, D,Wisniewski, SR(2009).STAR*D: Revising conventional wisdom.CNS Drugs,23,627-647.
28. Ryu, JS,Lee, YM,Kim, YS(2021).Association between BDNF polymorphism and depressive symptoms in patients newly diagnosed with type 2 diabetes mellitus.Yonsei Med J,62,359-365.
29. Su, TP,Chen, MH,Li, CT(2019).Correction: Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression.Neuropsychopharmacology,44,655-656.
30. Tsai, SJ(2018).Critical issues in BDNF Val66Met genetic studies of neuropsychiatric disorders.Front Mol Neurosci,11,156.
31. Verhagen, M,van der Meij, A,van Deurzen, PA(2010).Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: Effects of gender and ethnicity.Mol Psychiatry,15,260-271.
32. World Health Organization(2001).Mental Health: New Understanding, New Hope.Geneva, Switzerland:World Health Organization.
33. Yan, T,Wang, L,Kuang, W(2014).Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: A systematic review and meta-analysis.Asia Pac Psychiatry,6,241-251.
34. Zou, YF,Ye, DQ,Feng, XL(2010).Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder.Eur Neuropsychopharmacol,20,535-544.